vs

Side-by-side financial comparison of INVO Fertility, Inc. (IVF) and NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC). Click either name above to swap in a different company.

NEUROONE MEDICAL TECHNOLOGIES Corp is the larger business by last-quarter revenue ($2.9M vs $1.8M, roughly 1.6× INVO Fertility, Inc.). NEUROONE MEDICAL TECHNOLOGIES Corp runs the higher net margin — -49.7% vs -150.5%, a 100.8% gap on every dollar of revenue. On growth, INVO Fertility, Inc. posted the faster year-over-year revenue change (22.6% vs -11.7%). INVO Fertility, Inc. produced more free cash flow last quarter ($-1.8M vs $-3.2M). Over the past eight quarters, NEUROONE MEDICAL TECHNOLOGIES Corp's revenue compounded faster (44.9% CAGR vs 12.8%).

INVO Fertility, Inc. is a specialized healthcare company focused on delivering accessible assisted reproductive technology solutions. It develops, manufactures and markets the patented INVOcell intravaginal culture system for in vitro fertilization procedures, serving fertility clinics and patients across North America, Europe and other global regions, with a mission to reduce barriers to high-quality fertility care.

NeuroOne Medical Technologies Corp is a medical technology company specializing in the development and commercialization of diagnostic and therapeutic neurological devices for conditions including epilepsy, movement disorders, and chronic pain. Its core products include minimally invasive cortical monitoring electrodes and neurostimulation systems, primarily serving neurology and neurosurgical care providers across North America.

IVF vs NMTC — Head-to-Head

Bigger by revenue
NMTC
NMTC
1.6× larger
NMTC
$2.9M
$1.8M
IVF
Growing faster (revenue YoY)
IVF
IVF
+34.3% gap
IVF
22.6%
-11.7%
NMTC
Higher net margin
NMTC
NMTC
100.8% more per $
NMTC
-49.7%
-150.5%
IVF
More free cash flow
IVF
IVF
$1.4M more FCF
IVF
$-1.8M
$-3.2M
NMTC
Faster 2-yr revenue CAGR
NMTC
NMTC
Annualised
NMTC
44.9%
12.8%
IVF

Income Statement — Q3 FY2025 vs Q1 FY2026

Metric
IVF
IVF
NMTC
NMTC
Revenue
$1.8M
$2.9M
Net Profit
$-2.6M
$-1.4M
Gross Margin
54.2%
Operating Margin
-93.1%
-59.0%
Net Margin
-150.5%
-49.7%
Revenue YoY
22.6%
-11.7%
Net Profit YoY
-62.2%
-180.5%
EPS (diluted)
$-0.77
$-0.03

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IVF
IVF
NMTC
NMTC
Q4 25
$2.9M
Q3 25
$1.8M
$2.7M
Q2 25
$1.9M
$1.7M
Q1 25
$1.6M
$1.4M
Q4 24
$1.7M
$3.3M
Q3 24
$1.4M
$272.3K
Q2 24
$1.8M
$825.8K
Q1 24
$1.6M
$1.4M
Net Profit
IVF
IVF
NMTC
NMTC
Q4 25
$-1.4M
Q3 25
$-2.6M
$-1.6M
Q2 25
$-5.3M
$-1.5M
Q1 25
$-17.4M
$-2.3M
Q4 24
$-3.6M
$1.8M
Q3 24
$-1.6M
Q2 24
$-2.2M
$-2.8M
Q1 24
$-1.6M
$-2.9M
Gross Margin
IVF
IVF
NMTC
NMTC
Q4 25
54.2%
Q3 25
55.8%
Q2 25
53.9%
Q1 25
35.2%
55.6%
Q4 24
41.4%
58.9%
Q3 24
31.0%
51.8%
Q2 24
53.1%
34.1%
Q1 24
45.3%
28.3%
Operating Margin
IVF
IVF
NMTC
NMTC
Q4 25
-59.0%
Q3 25
-93.1%
-50.0%
Q2 25
-160.4%
-111.2%
Q1 25
-1042.1%
-193.3%
Q4 24
-202.0%
52.3%
Q3 24
-90.7%
Q2 24
-100.9%
-338.3%
Q1 24
-95.7%
-209.5%
Net Margin
IVF
IVF
NMTC
NMTC
Q4 25
-49.7%
Q3 25
-150.5%
-59.1%
Q2 25
-283.6%
-88.5%
Q1 25
-1060.1%
-163.8%
Q4 24
-211.3%
54.5%
Q3 24
-113.8%
Q2 24
-122.2%
-335.1%
Q1 24
-101.3%
-207.3%
EPS (diluted)
IVF
IVF
NMTC
NMTC
Q4 25
$-0.03
Q3 25
$-0.77
$-0.05
Q2 25
$-13.30
$-0.03
Q1 25
$-12.53
$-0.07
Q4 24
$14.86
$0.06
Q3 24
$-15.11
Q2 24
$-22.39
$-0.10
Q1 24
$-7.55
$-0.11

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IVF
IVF
NMTC
NMTC
Cash + ST InvestmentsLiquidity on hand
$3.6M
Total DebtLower is stronger
$2.0M
Stockholders' EquityBook value
$5.8M
$6.4M
Total Assets
$18.8M
$8.6M
Debt / EquityLower = less leverage
0.34×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IVF
IVF
NMTC
NMTC
Q4 25
$3.6M
Q3 25
$6.6M
Q2 25
$8.0M
Q1 25
$1.3M
Q4 24
$1.1M
Q3 24
$1.5M
Q2 24
$1.6M
Q1 24
$2.4M
Total Debt
IVF
IVF
NMTC
NMTC
Q4 25
Q3 25
$2.0M
Q2 25
$4.8M
Q1 25
Q4 24
$7.5M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
IVF
IVF
NMTC
NMTC
Q4 25
$6.4M
Q3 25
$5.8M
$7.1M
Q2 25
$2.6M
$8.2M
Q1 25
$3.3M
$1.1M
Q4 24
$12.7M
$2.9M
Q3 24
$-23.3K
$822.0K
Q2 24
$1.4M
$3.0M
Q1 24
$10.2K
$3.9M
Total Assets
IVF
IVF
NMTC
NMTC
Q4 25
$8.6M
Q3 25
$18.8M
$10.8M
Q2 25
$19.3M
$10.8M
Q1 25
$31.7M
$4.5M
Q4 24
$46.4M
$6.5M
Q3 24
$17.0M
$5.4M
Q2 24
$17.8M
$4.9M
Q1 24
$17.3M
$5.4M
Debt / Equity
IVF
IVF
NMTC
NMTC
Q4 25
Q3 25
0.34×
Q2 25
1.83×
Q1 25
Q4 24
0.59×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IVF
IVF
NMTC
NMTC
Operating Cash FlowLast quarter
$-1.8M
$-3.1M
Free Cash FlowOCF − Capex
$-1.8M
$-3.2M
FCF MarginFCF / Revenue
-101.6%
-109.1%
Capex IntensityCapex / Revenue
0.5%
1.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-7.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IVF
IVF
NMTC
NMTC
Q4 25
$-3.1M
Q3 25
$-1.8M
$-1.5M
Q2 25
$-1.7M
$-1.5M
Q1 25
$-3.5M
$-56.1K
Q4 24
$-617.4K
$208.0K
Q3 24
$-640.8K
$-11.0M
Q2 24
$-1.5M
$-2.4M
Q1 24
$-260.6K
$-2.2M
Free Cash Flow
IVF
IVF
NMTC
NMTC
Q4 25
$-3.2M
Q3 25
$-1.8M
Q2 25
$-1.7M
$-1.5M
Q1 25
$-3.6M
Q4 24
$-696.3K
$183.6K
Q3 24
$-11.1M
Q2 24
$-1.5M
$-2.4M
Q1 24
$-310.3K
$-2.2M
FCF Margin
IVF
IVF
NMTC
NMTC
Q4 25
-109.1%
Q3 25
-101.6%
Q2 25
-92.6%
-89.0%
Q1 25
-216.9%
Q4 24
-40.6%
5.6%
Q3 24
-4088.4%
Q2 24
-82.3%
-287.6%
Q1 24
-19.7%
-160.2%
Capex Intensity
IVF
IVF
NMTC
NMTC
Q4 25
1.4%
Q3 25
0.5%
Q2 25
0.5%
2.8%
Q1 25
0.9%
Q4 24
4.6%
0.7%
Q3 24
0.0%
44.1%
Q2 24
3.0%
1.8%
Q1 24
3.2%
2.3%
Cash Conversion
IVF
IVF
NMTC
NMTC
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.12×
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons